Trials conducted between 2001 and 2007 demonstrated statistically significant reductions in body fat, although the larger Phase IIb OPTIONS trial did not replicate these findings at sufficient magnitude for regulatory approval, and formal development was discontinued in 2007
The attachment of the 4-phosphopantetheine, from CoA, to the proteins indicated, occurs on a conserved Ser residue via a phosphodiester linkage
For type 1 and type 2 diabetes, to improve blood sugar control in conjunction with diet and exercise
Dermatol Surg
7.3 Nanocarriers with stimuli-responsive properties for targeted activity Stimuli-responsive nanocarriers are a more sophisticated technique of invoking site-specific release, which is the key to reducing side effects and thus increasing the therapeutic effect
But in this space, the more common pattern is stacking to compensate for weak evidence, not stacking because combination efficacy is proven